Oppenheimer & Co’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Oppenheimer & Co's PTGX Position: Q3 2026 in Review
Oppenheimer & Co held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 1,900 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.
Oppenheimer & Co first reported a position in PTGX in Q1 2026 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Oppenheimer & Co held 1,900 shares of Protagonist Therapeutics worth $268K as of Q3 2026.
- Oppenheimer & Co left its Protagonist Therapeutics share count unchanged in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1488 holding.
- Oppenheimer & Co first reported a position in Protagonist Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.